UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Annals of oncology, 2015-02, Vol.26 (2), p.313-320

2015

Volltextzugriff (PDF)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

British journal of cancer, 2013-04, Vol.108 (7), p.1408-1414

2013

Volltextzugriff (PDF)

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

European journal of surgical oncology, 2009-10, Vol.35 (10), p.1048-1054

2009

Volltextzugriff (PDF)

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Clinical cancer research, 2011-09, Vol.17 (18), p.6012-6020

2011

Volltextzugriff (PDF)

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

The New England journal of medicine, 2009-02, Vol.360 (7), p.679-691

2009

Volltextzugriff (PDF)

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS3-01-GS3-01

2018

Volltextzugriff (PDF)

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Breast cancer research and treatment, 2008-11, Vol.112 (1), p.203-213

2008

Volltextzugriff (PDF)

Efficacy of tamoxifen plus or minus aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

British journal of cancer, 2013-04, Vol.108 (7), p.1408-1414

2013

Volltextzugriff (PDF)

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Clinical cancer research, 2011-12, Vol.17 (24), p.7828-7834

2011

Volltextzugriff (PDF)

Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14575-14575

2008

Volltextzugriff (PDF)

Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer: A Phase II Study

Strahlentherapie und Onkologie, 2011-02, Vol.187 (2), p.100-107

2011

Volltextzugriff (PDF)

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.LBA4009-LBA4009

2005

Volltextzugriff (PDF)

Venous thromboembolism in cancer patients: a population-based cohort study

Blood, 2021-04, Vol.137 (14), p.1959-1969

2021

Volltextzugriff (PDF)

Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Annals of oncology, 2024-03, Vol.35 (3), p.327-327

2024

Volltextzugriff (PDF)

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

European journal of cancer (1990), 2021-07, Vol.151, p.3-13

2021

Volltextzugriff (PDF)

VTE with Amivantamab plus Chemotherapy in NSCLC

The New England journal of medicine, 2024-02, Vol.390 (6), p.578-580

2024

Volltextzugriff (PDF)

FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin

Journal of cell science, 2012-12, Vol.125 (Pt 23), p.5690-5701

2012

Volltextzugriff (PDF)

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

Scientific reports, 2019-04, Vol.9 (1), p.5548, Article 5548

2019

Volltextzugriff (PDF)

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

Virchows Archiv : an international journal of pathology, 2024-02, Vol.484 (2), p.169-179

2024

Volltextzugriff (PDF)

122P Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience

Annals of oncology, 2024-09, Vol.35, p.S262-S263

2024

Volltextzugriff (PDF)

1844MO Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy

Annals of oncology, 2023-10, Vol.34, p.S999-S999

2023

Volltextzugriff (PDF)

Unanswered questions in cancer‐associated thrombosis

British journal of haematology, 2022-09, Vol.198 (5), p.812-825

2022

Volltextzugriff (PDF)

PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

Thrombosis research, 2022-05, Vol.213, p.S12-S12

2022

Volltextzugriff (PDF)

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies

Hämostaseologie, 2024-02, Vol.44 (1), p.40-48

2024

Volltextzugriff (PDF)

Adverse cardiovascular events in patients with cancer: a biomarker-enhanced clinical risk score

European heart journal, 2024-10, Vol.45 (Supplement_1)

2024

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(55)

Sprache

Englisch
(54)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(18)
Humans
(16)
Female
(12)
Oncology
(11)
Middle Aged
(10)
Aged
(7)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Breast Neoplasms - Drug Therapy
(6)
Tumors
(6)
Biological And Medical Sciences
(5)
Cancer
(5)
Cancer Therapies
(5)
Hematology
(5)
Male
(5)
Medical Sciences
(5)
Medicine
(5)
Patients
(5)
Breast Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Efficacy of tamoxifen plus or minus aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result

Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer: A Phase II Study

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer

Venous thromboembolism in cancer patients: a population-based cohort study

Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

VTE with Amivantamab plus Chemotherapy in NSCLC

FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

122P Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience

1844MO Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy

Unanswered questions in cancer‐associated thrombosis

PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies

Adverse cardiovascular events in patients with cancer: a biomarker-enhanced clinical risk score

Suchergebnisse filtern